News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Serologicals Corporation (SERO) Announces Expanded Multi-Year Distribution Agreement With Novo Nordisk A/S (NVO)



3/16/2006 12:37:20 PM

ATLANTA--(BUSINESS WIRE)--March 16, 2006--Celliance Corporation, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), announced today the execution of an expanded four-year supply agreement with Novo Nordisk A/S that provides Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES